# Effects of Tipranavir (With Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity in Healthy Volunteers

> **NCT02243553** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 34 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Tipranavir capsule
- **DRUG:** Tipranavir solution
- **DRUG:** Ritonavir capsule
- **DRUG:** Caffeine
- **DRUG:** Warfarin sodium
- **DRUG:** Vitamin K
- **DRUG:** Omeprazole
- **DRUG:** Dextromethorphan hydrobromide
- **DRUG:** Midazolam injection
- **DRUG:** Midazolam oral solution
- **DRUG:** Digoxin tablet
- **DRUG:** Digoxin injection

## Key facts

- **NCT ID:** NCT02243553
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2006-07
- **Final completion:** —
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2014-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02243553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02243553, "Effects of Tipranavir (With Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02243553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*